Cencora, Inc. (NYSE:COR) Shares Bought by Mizuho Securities USA LLC

Mizuho Securities USA LLC grew its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 167.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,110 shares of the company's stock after buying an additional 21,351 shares during the quarter. Mizuho Securities USA LLC's holdings in Cencora were worth $7,677,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of COR. New Millennium Group LLC purchased a new stake in Cencora in the second quarter worth about $26,000. TFO Wealth Partners LLC purchased a new stake in Cencora during the 1st quarter valued at $30,000. LRI Investments LLC purchased a new stake in Cencora during the 1st quarter valued at $31,000. MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the 2nd quarter worth $30,000. Finally, Concord Wealth Partners purchased a new stake in shares of Cencora in the 3rd quarter worth $30,000. 97.52% of the stock is owned by institutional investors.

Cencora Stock Performance

Shares of COR stock traded down $2.61 during mid-day trading on Friday, hitting $240.24. The stock had a trading volume of 1,844,676 shares, compared to its average volume of 1,239,838. Cencora, Inc. has a fifty-two week low of $194.23 and a fifty-two week high of $251.56. The firm has a market cap of $47.34 billion, a PE ratio of 31.99, a PEG ratio of 1.60 and a beta of 0.44. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The company's 50-day simple moving average is $232.62 and its 200-day simple moving average is $231.03.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio (DPR) is currently 27.16%.

Wall Street Analyst Weigh In

COR has been the subject of several recent analyst reports. UBS Group upped their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 21st. Bank of America reaffirmed a "neutral" rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Leerink Partners cut their price objective on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a report on Monday, October 7th. Finally, Barclays raised their target price on shares of Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $271.20.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares of the company's stock, valued at $67,223,750.40. The trade was a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 15.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.